Ascendis Pharma A/s

This study tests if a once-weekly growth hormone injection (lonapegsomatropin) works as well as a daily one (somatropin) for helping children with short stature grow taller. About 186 children with Turner syndrome, SHOX deficiency, short stature at birth, or idiopathic short stat…

This study tests a once-weekly injection called navepegritide in 24 adolescents (ages 12-18) with achondroplasia, the most common form of dwarfism. The goal is to see if it safely increases growth rate over 52 weeks compared to a placebo. The treatment aims to manage the conditio…

This study tests a weekly injection called TransCon CNP in infants under 2 years old with achondroplasia, the most common form of dwarfism. The goal is to see if it safely improves growth compared to a placebo. About 72 babies will take part, receiving either the drug or a dummy …

This study is a pregnancy registry that collects information from women who took YORVIPATH for hypoparathyroidism around the time of pregnancy or while breastfeeding. Researchers will follow about 50 women and their babies for at least a year to watch for complications, birth def…

This study looks at how much of the drug palopegteriparatide (YORVIPATH) passes into breast milk. It involves 10 lactating women with hypoparathyroidism who are already taking the drug and choose to breastfeed. Researchers will collect milk samples to measure drug levels, helping…